Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399065 | 1.00 | KMT2A (0.61) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL2902111 | 0.92 | ALDH1A1 (0.69) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399129 | 0.84 | ALDH1A1 (0.61) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399127 | 0.84 | ALDH1A1 (0.61) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399060 | 0.83 | ALDH1A1 (0.63) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399062 | 0.83 | ALDH1A1 (0.63) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399069 | 0.80 | KMT2A (0.68) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399067 | 0.80 | KMT2A (0.68) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399046 | 0.80 | KMT2A (0.62) | KMT2AALDH1A1POLBL3MBTL1MAPK1 | |
| SCHEMBL1399044 | 0.80 | KMT2A (0.62) | KMT2AALDH1A1POLBL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022064-B2 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2011-09-20 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | claimed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | F2R, F2RL1, FPR1 | KMT2A 4020/4885ALDH1A1 1195/4885POLB 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.